Pomalidomide therapy for multiple myeloma and myelofibrosis: an update

@article{Lacy2011PomalidomideTF,
  title={Pomalidomide therapy for multiple myeloma and myelofibrosis: an update},
  author={M. Lacy and A. Tefferi},
  journal={Leukemia & Lymphoma},
  year={2011},
  volume={52},
  pages={560 - 566}
}
Thalidomide possesses potent anti-inflammatory, immunomodulatory, and antiangiogenic properties. Thalidomide combined with corticosteroids is therapeutically active in multiple myeloma and myelofibrosis (MF). Lenalidomide and pomalidomide are second-generation immunomodulatory drugs (IMiDs) that were created by chemical modification of thalidomide with the intent to reduce toxicity and enhance therapeutic activity. Both drugs have also been shown to be active in the treatment of myeloma and MF… Expand
15 Citations
Immunomodulatory agents in myelofibrosis
  • 16
  • Highly Influenced
Immunomodulation as a therapeutic strategy in the treatment of multiple myeloma.
  • 15
Clinical and laboratory features of myelofibrosis and limitations of current therapies.
  • 26
Cereblon binding molecules in multiple myeloma.
  • 31
Immunotherapy Strategies Against Multiple Myeloma
  • J. Ma, Q. Li, +8 authors Q. Liu
  • Medicine
  • Technology in Cancer Research & Treatment
  • 2017
  • 3
...
1
2
...

References

SHOWING 1-10 OF 67 REFERENCES
Pomalidomide is active in the treatment of anemia associated with myelofibrosis.
  • 194
  • PDF
Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma.
  • M. Lacy, S. Hayman, +17 authors S. Rajkumar
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009
  • 285
Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma.
  • S. Schey, P. Fields, +5 authors A. Dalgleish
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2004
  • 290
Acute lung toxicity related to pomalidomide.
  • 26
Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)
  • 178
  • PDF
Lenalidomide therapy in myelofibrosis with myeloid metaplasia.
  • 237
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
  • 1,130
Antitumor activity of thalidomide in refractory multiple myeloma.
  • 2,344
  • PDF
...
1
2
3
4
5
...